EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multicentre Trial Evaluating the Safety and Tolerability of Estetrol-Drospirenone Combined Oral Contraceptive in Postmenarchal Female Adolescents

Angelica Lindén Hirschberg iD, Lali Pkhaladze iD, Kristina Gemzell-Danielsson iD, Kai Haldre, Kateryna Ruban, Nina Flerin, Guillaume Chatel, Dan Apter iD

Journal of Clinical Medicine · 13.12.2025 · 14 (24) · 8832

DOI: 10.3390/jcm14248832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.12.2025. Verfasst von Angelica Lindén Hirschberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Karolinska Institutet, 17177 Stockholm, Sweden. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Estetra SRL, Estetra SRL, a wholly owned subsidiary of Gedeon Richter Plc., Liège, Belgium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aims to evaluate the safety and tolerability of estetrol/drospirenone in adolescents.

Methods

In this Phase 3 open-label study, postmenarchal adolescents (12–17 years) received estetrol (E4)/drospirenone (DRSP) 15 mg/3 mg orally for six cycles (24 active/4 placebo regimen). Safety was evaluated through adverse event (AE) reporting. Participants also recorded daily pill intake, bleeding/spotting, dysmenorrhea, and pain medication use in e-diaries. Descriptive statistics were used.

Results

Of 112 enrolled participants, 105 received treatment (mean age: 15.2 years), and 84.8% were completers. No serious treatment-related AEs or safety concerns were observed. Nausea and dysmenorrhea (each 1.9%) were the most common treatment-related AEs. Over 71% of participants took all tablets in each cycle. The percentage of participants with unscheduled bleeding and/or spotting decreased from 45.8% (Cycle 1) to 14.5% (Cycle 5), and the number of days with unscheduled bleeding and/or spotting decreased from nine to six days per cycle. The scheduled bleeding and/or spotting rate ranged between 77.4% and 90.5%, with a duration decreasing from six to four days in Cycle 1 to Cycle 5. Absence of scheduled bleeding increased from 9.5% in Cycle 3 to 22.6% in Cycle 5. The proportion of participants reporting dysmenorrhea decreased by 34.8%, with a median visual analogue scale score dropping from 5.0 at baseline to 3.7 at Cycle 6. Pain medication use decreased from 63.9% to 31.6% in Cycle 6.

Conclusions

The use of E4/DRSP in adolescents raised no safety concerns, was well tolerated, resulted in a clear and stable cyclic bleeding pattern, and reduced pain associated with dysmenorrhea.

Schlagwörter

Stichwörter der Autor:innen

adolescentscycle controldysmenorrheaestetrol/drospirenonesafetytolerability

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, 17176 Stockholm, Sweden.
  • Prof. Zhordania and Prof. Khomasuridze Institute of Reproductology, Tbilisi 0186, Georgia.
  • East Tallinn Central Hospital Women's Clinic, 10138 Tallinn, Estonia.
  • Estetra SRL, a Wholly Owned Subsidiary of Gedeon Richter Plc., 4000 Liège, Belgium.
  • Department of Obstetrics and Gynaecology, University of Helsinki, 00100 Helsinki, Finland.

ORCID-Profile: Angelica Lindén Hirschberg, Lali Pkhaladze, Kristina Gemzell-Danielsson, Dan Apter

Förderung

  • Estetra SRL
  • Estetra SRL, a wholly owned subsidiary of Gedeon Richter Plc., Liège, Belgium

Zitieren

APA

Lindén Hirschberg, A., Pkhaladze, L., Gemzell-Danielsson, K., Haldre, K., Ruban, K., Flerin, N., Chatel, G., & Apter, D. (2025). Multicentre Trial Evaluating the Safety and Tolerability of Estetrol-Drospirenone Combined Oral Contraceptive in Postmenarchal Female Adolescents. Journal of Clinical Medicine, 14(24), 8832. https://doi.org/10.3390/jcm14248832

Vancouver

Lindén Hirschberg A, Pkhaladze L, Gemzell-Danielsson K, Haldre K, Ruban K, Flerin N, et al. Multicentre Trial Evaluating the Safety and Tolerability of Estetrol-Drospirenone Combined Oral Contraceptive in Postmenarchal Female Adolescents. Journal of Clinical Medicine. 2025;14(24):8832. doi:10.3390/jcm14248832

BibTeX
@article{LindnHirschberg2025,
  author = {Lindén Hirschberg, Angelica and Pkhaladze, Lali and Gemzell-Danielsson, Kristina and Haldre, Kai and Ruban, Kateryna and Flerin, Nina and Chatel, Guillaume and Apter, Dan},
  title = {Multicentre Trial Evaluating the Safety and Tolerability of Estetrol-Drospirenone Combined Oral Contraceptive in Postmenarchal Female Adolescents},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {24},
  pages = {8832},
  doi = {10.3390/jcm14248832}
}
Kostenlos starten →